Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Cytotoxic T-lymphocyte-associated Antigen-4 Blockage Can Induce Autoimmune Hypophysitis In Patients With Metastatic Melanoma And Renal Cancer.
J. Blansfield, Kimberly E. Beck, K. Tran, J. Yang, M. Hughes, U. Kammula, R. Royal, S. Topalian, Leah R. Haworth, C. Levy, S. Rosenberg, R. Sherry
Published 2005 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) is an immunoregulatory molecule expressed by activated T cells and resting CD4CD25 T cells. In patients with advanced melanoma, our group reported that administration of anti-CTLA-4 antibody mediated objective cancer regression in 13% of patients. This study also established that the blockade of CTLA-4 was associated with grade III/IV autoimmune manifestations that included dermatitis, enterocolitis, hepatitis, uveitis, and a single case of hypophysitis. Since this initial report, 7 additional patients with anti-CTLA-4 antibody-induced autoimmune hypophysitis have been accumulated. The characteristics, clinical course, laboratory values, radiographic findings, and treatment of these 8 patients are the focus of this report.
This paper references
Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.
Kristin M. Sanderson (2005)
Lymphocytic hypophysitis: non-invasive diagnosis and treatment by high dose methylprednisolone pulse therapy?
R. Kristof (1999)
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
E. Tivol (1995)
Panhypopituitarism in association with interferon-alpha treatment.
W. B. Chan (2004)
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
F. S. Hodi (2003)
Severe autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy in an adolescent girl with a novel AIRE mutation: response to immunosuppressive therapy.
L. Ward (1999)
Lymphocytic hypophysitis. Case report.
A. Ruelle (1999)
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
P. Waterhouse (1995)
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
P. Attia (2005)
P. Caturegli (2005)
Anterior hypophysitis and Hashimoto's disease in a young woman.
R. Goudie (1962)
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
G. Phan (2003)
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-CTLA-4
Peter Attia (2005)
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
H. Ueda (2003)
Isohormonal therapy of endocrine autoimmunity.
N. Schloot (1995)
Clinical case seminar: lymphocytic hypophysitis: clinicopathological findings.
E. Thodou (1995)
Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells.
Cynthia A Chambers (1997)
This paper is referenced by
Prostate cancer immunotherapy
D. McNeel (2007)
Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer.
A. Ribas (2007)
Ipilimumab: report and comment about the MDX010-020 clinical trial
Stefania Vittoria Luisa Nicoletti (2012)
Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma
Sebastian G Bernardo (2013)
Melanoma: From Darkness to Promise
J. M. G. Blesa (2010)
The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
Caroline J Voskens (2013)
Immuno-related endocrinopathy in patients treated with immune checkpoint inhibitors
D. I. Yudin (2020)
Beyond Cancer Vaccines: A Reason for Future Optimism With Immunomodulatory Therapy
M. Postow (2011)
Emerging therapies for melanoma
R. Katipamula (2008)
Immunotherapy of melanoma
P. Hersey (2010)
[Ipilimumab, a cause of autoimmune hypophysitis].
A. de Hollanda (2013)
L. Sposato (2014)
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.
J. Naidoo (2016)
From Japan with love: another tessera in the hypophysitis mosaic.
P. Caturegli (2013)
Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review.
A. Juszczak (2012)
Stat3 as a potential target for cancer immunotherapy.
M. Kortylewski (2007)
Prostate cancer as a model for tumour immunotherapy
C. Drake (2010)
Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient.
K. Kähler (2009)
Ipilimumab for advanced melanoma: a nursing perspective.
B. Ledezma (2009)
Immune‐related Adverse Events in Cancer Patients
D. Pallin (2018)
Ipilimumab-Induced Hypophysitis May Not Affect All Pituitary Cell Lines: A Case Report
A. Kotwal (2015)
Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy
C. S. Hinrichs (2016)
Checkpoint Blockade and Combinatorial Immunotherapies
K. Peggs (2007)
Immunomodulatory Molecules of the Immune System
Y. Saenger (2007)
Principles of adoptive T cell cancer therapy.
C. June (2007)
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review.
C. Friedman (2016)
Anticytotoxic T lymphocyte-associated antigen 4 treatment--can melanoma be cured at the expense of autoimmune disorders?
F. Lejeune (2006)
Cancer immunotherapy targeting T cell costimulatory molecules
Angela D. Pardee (2010)
The Extended CD 28 : B 7 Immunoglobulin Superfamily
A. Korman (2007)
Immunotherapy-induced autoimmune hypophysitis
Gautam Valecha (2019)
Human Monoclonal Antibodies from Transgenic Mice
N. Lonberg (2008)
Pitfalls or Promise in Prostate Cancer Immunotherapy—Which Is Winning?
S. Slovin (2008)See more